Stock Ratings / Health Care / GENB / earnings

ZYME (47) SRPT (35) SLS (35) TRVI (39) ⌘ Pro Terminal →

Generate Biomedicines Inc. (GENB) Next Earnings Date & Expected ±12.5% Move

$15.77 +2.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.81

Generate Biomedicines Inc. (GENB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $2.02B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GENB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GENB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Generate Biomedicines Inc. (NASDAQ: GENB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $15.77 (+2.54% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GENB ranks #184 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GENB compare to ZYME and SRPT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZYME (Zymeworks Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B) and SRPT (Sarepta Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GENB?

▼

Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.81 (+0.27%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GENB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY GENB SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 41% of 52W Range • RSI-14 at 52.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+14/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$14.34-15.7% Next Q

Q2 (-2Q)

Grade C$12.09+2.6% Next Q

Q3 (-1Q)

Grade C$12.41+27.1% Next Q

Current

Grade C-$15.77+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the GENB Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, GENB faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.00) or 200D SMA ($14.07) invalidates the momentum regime and cuts Target Base ($15.98) toward Bear Floor ($12.46).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GENB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “GENB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.97 Expected Swing

MODEL EARNINGS SETUP GAUGE

GENB Quantitative Pre-Earnings Setup: 61/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (61/100)Model Risk Weight (39/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	$0	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating GENB & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on GENB
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GENB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.86%📐 HORIZONTAL RANGE

2026-10-30O $14.86H $15.77L $14.25C $15.77VOL 1.17M

RES: $26.59SUP: $10.99SMA50: $15.00SMA200: $14.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GENB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GENB Butterfly Map → + Track GENB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GENB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GENB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GENB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GENB)

Health Care Rank #184 of 1016 ⚔️ ZYME vs GENB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GENB vs. ZYME, SRPT, SLS, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Generate Biomedicines Inc. (GENB) ranks #184 by composite RQD confidence (61/100, grade C-) and #262 by equity capitalization ($2.02B). Within this direct 5-issuer industry benchmark cohort, GENB leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GENB ACTIVE Generate Biomedicines Inc.	C-	61/100	—	—	—	+2.54%	$2.02B	Benchmark Subject
ZYME Zymeworks Inc.	D	47/100	—	—	-32.2%	-0.66%	$2.02B	/zyme-vs-genb →
SRPT Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-0.47%	$2.03B	/srpt-vs-genb →
SLS SELLAS Life Sciences Group Inc.	D-	35/100	—	—	-21.8%	-2.17%	$2.05B	/sls-vs-genb →
TRVI Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-genb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002100782

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Generate Biomedicines Inc. (GENB) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, GENB closed FY2025 with $330.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$330.2M	—

3. GENB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GENB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does GENB compare to ZYME and SRPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for GENB?

Where is GENB trading relative to its 50-day, 200-day, and 52-week technical levels?

GENB last traded at $15.77 (+2.54% on volume of 1,762,250 shares), positioning the stock +5.13% above its 50-day simple moving average ($15.00) and +12.08% above its 200-day simple moving average ($14.07). Across its 52-week range of $11.00 to $22.67, GENB sits at the 40.9% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.80 to $17.74).

GENB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is GENB's next earnings date?

Based on SEC filing cadence, Generate Biomedicines Inc. (GENB)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is GENB stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for GENB, spanning a range between $13.8 and $17.74.

Direct Sub-Reports: GENB RQD Cockpit GENB 12M Forecast GENB Earnings & Move GENB Dividends & DRIP GENB Insiders & 13F GENB Whale Options GENB Profit Sankey GENB News & Why